Department of Internal Medicine, Hanchuan People's Hospital of Hubei Province, Hanchuan, China.
Department of Neurology, Renmin Hospital, Hubei University of Medicine, Shiyan, China.
Panminerva Med. 2019 Dec;61(4):439-443. doi: 10.23736/S0031-0808.18.03475-4. Epub 2018 Jun 28.
To investigate the clinical efficiency and safeness of the combination of rosuvastatin and nimodipine in treating mild cognitive impairment of cerebral small vessel disease (CSVD) patients.
A total of 120 patients with mild cognitive impairment caused by CSVD were divided randomly into two groups: an observation group and a control group, each of which had 60 patients. In the observation group, patients were given rosuvastatin in combination with nimodipine, and other patients were given nimodipine in the control group. For the two groups, the course of treatment was six months. Before and after treatments, levels of total cholesterol (TC), triacylglycerol (TG), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), MMP-9 and high sensitivity C reactive protein (hs-CRP) were measured. Montreal Cognitive Assessment (MoCA) and activities of daily living (ADL) were also evaluated. Incidence of adverse reactions were compared between two groups.
The levels of TG, TC and LDL-C were decreased after treatment in the observation group (P<0.01), and these after-treatment levels were lower than the control group. Additionally, after treatment, the levels of MMP-9 and hs-CRP were significant lower in the observation group than the control group. The MoCA and ADL scores were higher in the observation group than the control group after treatment (P<0.05). Moreover, the overall effective rate were higher in the observation group (91.7%) than the control group (65.0%) (P<0.01), while there was no significant difference of the rate of adverse reactions between the observation group and the control one (10.0% vs. 8.3%) (P>0.05).
The combination of rosuvastatin and nimodipine was safe and effective in treating mild cognitive impairment of CSVD patients.
研究瑞舒伐他汀与尼莫地平联合治疗脑小血管病（CSVD）轻度认知障碍患者的临床疗效及安全性。
将 120 例 CSVD 所致轻度认知障碍患者随机分为观察组和对照组，每组 60 例。观察组给予瑞舒伐他汀联合尼莫地平治疗，对照组给予尼莫地平治疗。两组疗程均为 6 个月。治疗前后测定两组患者总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、基质金属蛋白酶-9（MMP-9）和高敏 C 反应蛋白（hs-CRP）水平，采用蒙特利尔认知评估量表（MoCA）和日常生活活动能力量表（ADL）评估患者认知功能和日常生活能力。比较两组不良反应发生率。
观察组治疗后 TG、TC、LDL-C 水平降低（P<0.01），且治疗后低于对照组；观察组 MMP-9、hs-CRP 水平低于对照组（P<0.05）；观察组治疗后 MoCA、ADL 评分高于对照组（P<0.05）。观察组总有效率为 91.7%，高于对照组的 65.0%（P<0.01）；观察组不良反应发生率为 10.0%，与对照组的 8.3%比较差异无统计学意义（P>0.05）。
瑞舒伐他汀与尼莫地平联合治疗 CSVD 轻度认知障碍患者安全有效。
